Miovisin (Acetylcholine Chloride)

Acetylcholine Chloride, the active ingredient in Miovisin, is a cholinergic agonist presented as a solution for intraocular use. It is employed to lower intraocular pressure and to induce miosis in patients with glaucoma and related ocular conditions.

GNH USA supplies Miovisin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miovisin acts on the ocular cholinergic pathway to manage conditions that benefit from pupil constriction and pressure reduction.

Glaucoma: lowers intraocular pressure to help preserve optic nerve function. Ocular hypertension: reduces elevated eye pressure in patients at risk of glaucoma. Intraocular surgery: induces miosis to improve surgical visualization and outcomes.

Adverse reactions may occur following intraocular administration of Miovisin.

Common Side Effects: - Eye irritation or burning sensation - Transient blurred vision - Headache - Tearing or excessive lacrimation - Photophobia - Mild conjunctival redness

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis) - Allergic hypersensitivity reactions - Acute angle‑closure glaucoma - Systemic cholinergic effects such as bradycardia - Marked hypotension - Persistent corneal edema

Miovisin should be used with attention to specific safety considerations.

Contraindicated in narrow‑angle glaucoma: risk of precipitating acute closure. Caution in asthma or COPD: cholinergic stimulation may exacerbate bronchospasm. Avoid concurrent use with systemic anticholinergic agents: may reduce efficacy. Monitor intraocular pressure after administration to ensure therapeutic response. Store at room temperature: keep in the original container, protect from light and moisture.

Miovisin may interact with other ophthalmic or systemic agents.

Major Interactions (Avoid): - Systemic cholinesterase inhibitors (e.g., neostigmine) - Other miotic agents (e.g., pilocarpine) - Anticholinergic drugs that block muscarinic receptors

Moderate Interactions (Monitor Closely): - Topical anesthetic eye drops (may increase corneal toxicity) - Non‑steroidal anti‑inflammatory eye drops (potential for additive irritation) - Systemic antihistamines (may diminish miotic effect)